Ascendis Pharma A/S - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ASND Nasdaq 2836 ascendispharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascendis Pharma A/S

Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market - Oct 21st, 2026 5:00 am
RBC Capital names top healthcare stocks as sector upgraded to overweight - Oct 20th, 2026 1:27 pm
ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug - Oct 16th, 2026 2:30 pm
Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia - Oct 16th, 2026 6:58 am
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children - Oct 16th, 2026 6:29 am
Liberty All-Star® Growth Fund, Inc. September 2026 Monthly Update - Oct 14th, 2026 11:50 am
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Oct 7th, 2026 8:37 am
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 - Oct 6th, 2026 7:15 am
This Biotech’s Proprietary Platform Could Unlock Its Next Growth Phase - Oct 5th, 2026 7:47 am
Ascendis Pharma (ASND) Authorizes $400M Share Buyback - Sep 20th, 2026 8:55 pm
Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs - Sep 19th, 2026 4:09 am
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost? - Sep 17th, 2026 2:55 pm
BioMarin Stops Voxzogo Development for Noonan Syndrome - Sep 16th, 2026 10:01 am
Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says - Sep 16th, 2026 8:46 am
Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls - Sep 15th, 2026 7:35 am
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday - Sep 15th, 2026 7:12 am
Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback - Sep 15th, 2026 2:37 am
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases - Sep 14th, 2026 4:00 pm
Ascendis Announces Planned $400 Million Share Repurchase Program - Sep 14th, 2026 4:00 pm
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Sep 12th, 2026 11:02 am